Should I buy or sell Insulet stock right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 3 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PODD shares. View PODD analyst ratings or view top-rated stocks .

What is Insulet's stock price target for 2024?

18 analysts have issued 1-year price targets for Insulet's shares. Their PODD share price targets range from $184.00 to $330.00. On average, they anticipate the company's share price to reach $239.18 in the next twelve months. This suggests a possible upside of 35.0% from the stock's current price. View analysts price targets for PODD or view top-rated stocks among Wall Street analysts .

How have PODD shares performed in 2024?

Insulet's stock was trading at $216.98 at the beginning of 2024. Since then, PODD stock has decreased by 18.3% and is now trading at $177.19. View the best growth stocks for 2024 here .

Are investors shorting Insulet?

Insulet saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,260,000 shares, an increase of 44.9% from the April 30th total of 2,940,000 shares. Based on an average daily trading volume, of 947,900 shares, the days-to-cover ratio is presently 4.5 days. View Insulet's Short Interest .

When is Insulet's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our PODD earnings forecast .

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) released its quarterly earnings data on Thursday, May, 9th. The medical instruments supplier reported $0.73 EPS for the quarter, beating the consensus estimate of $0.39 by $0.34. The medical instruments supplier earned $441.70 million during the quarter, compared to analysts' expectations of $424.05 million. Insulet had a net margin of 13.14% and a trailing twelve-month return on equity of 34.06%. The company's revenue for the quarter was up 23.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.23 earnings per share.

What ETFs hold Insulet's stock?

ETFs with the largest weight of Insulet (NASDAQ:PODD) stock in their portfolio include BTD Capital Fund (DIP) , First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) , Global X Telemedicine & Digital Health ETF (EDOC) , Fidelity Digital Health ETF (FDHT) , Fidelity Disruptive Medicine ETF (FMED) , Goldman Sachs Future Health Care Equity ETF (GDOC) , Tema Cardiovascular and Metabolics ETF (HRTS) and Invesco Focused Discovery Growth ETF (IVDG) .

What guidance has Insulet issued on next quarter's earnings?

Insulet updated its second quarter 2024 earnings guidance on Thursday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $456.0 million-$467.9 million, compared to the consensus revenue estimate of $457.8 million.

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com . Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA) , DexCom (DXCM) , Netflix (NFLX) , Alibaba Group (BABA) , Tesla (TSLA) , Block (SQ) , Walt Disney (DIS) , Salesforce (CRM) , Roku (ROKU) and Trade Desk (TTD) .

Who are Insulet's major shareholders?

Insulet's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.71%), Capital Research Global Investors (10.80%), Baillie Gifford & Co. (2.06%), Clearbridge Investments LLC (1.81%), William Blair Investment Management LLC (1.36%) and Westfield Capital Management Co. LP (0.67%). Insiders that own company stock include Bret Christensen , Charles Alpuche , Dan Manea , James Hollingshead , Luciana Borio , Michael P Spears , Prem Singh , Sally Crawford , Shacey Petrovic , Timothy J Scannell and Wayde D Mcmillan . View institutional ownership trends .

How do I buy shares of Insulet?

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PODD

Insulet (PODD) Stock Price, News & Analysis

→ Warren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace) (Ad)

Free PODD Stock Alerts

$177.19

+1.24 (+0.70%)

(As of 05/31/2024 ET)

Compare

Today's Range: $175.85
▼
$180.60
50-Day Range: $161.02
▼
$187.27
52-Week Range: $125.82
▼
$298.95

Volume: 1.49 million shs
Average Volume: 1.03 million shs
Market Capitalization: $12.41 billion

P/E Ratio: 53.69
Dividend Yield: N/A
Price Target: $239.18

Insulet MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 35.0% Upside
$239.18 Price Target
Short Interest: Bearish
6.08% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.20
Upright™ Environmental Score
News Sentiment: 1.03
Based on 13 Articles This Week
Insider Trading: Selling Shares
$596,970 Sold Last Quarter
Proj. Earnings Growth: 20.90%
From $3.11 to $3.76 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.91 out of 5 stars

Medical Sector

26th out of 929 stocks

Surgical & Medical Instruments Industry

7th out of 101 stocks

4.4

Analyst's Opinion

Consensus Rating
Insulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 15 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Insulet has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Read more about Insulet's stock forecast and price target.

1.0

Short Interest

Percentage of Shares Shorted
6.08% of the outstanding shares of Insulet have been sold short.
Short Interest Ratio / Days to Cover
Insulet has a short interest ratio ("days to cover") of 4.5.
Change versus previous month
Short interest in Insulet has recently increased by 44.90%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Insulet does not currently pay a dividend.
Dividend Growth
Insulet does not have a long track record of dividend growth.

4.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Insulet has received a 80.74% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Insulin pumps" product. See details.
Environmental Sustainability
The Environmental Impact score for Insulet is -1.20.

3.9

News and Social Media Coverage

News Sentiment
Insulet has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Insulet this week, compared to 9 articles on an average week.
Search Interest
15 people have searched for PODD on MarketBeat in the last 30 days. This is an increase of 36% compared to the previous 30 days.
MarketBeat Follows
7 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $596,970.00 in company stock.
Percentage Held by Insiders
Only 0.47% of the stock of Insulet is held by insiders.
Read more about Insulet's insider trading history.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Insulet are expected to grow by 20.90% in the coming year, from $3.11 to $3.76 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Insulet is 53.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.39.
Price to Earnings Ratio vs. Sector
The P/E ratio of Insulet is 53.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 172.88.
Price to Earnings Growth Ratio
Insulet has a PEG Ratio of 3.10. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Insulet has a P/B Ratio of 15.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Read more about Insulet's valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Weiss Ratings

The ONE AI Stock to own now. (It’s not Nvidia.)

Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …

Click here to see the presentation now.

About Insulet Stock (NASDAQ:PODD)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

PODD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PODD Stock News Headlines

May 31 at 5:14 AM | insidertrades.com

Timothy J. Scannell Sells 3,300 Shares of Insulet Co. (NASDAQ:PODD) Stock

May 30 at 9:26 AM | americanbankingnews.com

Insulet (NASDAQ:PODD) Now Covered by Redburn Atlantic

May 28, 2024 | businesswire.com

Insulet to Present at the Jefferies Global Healthcare Conference

May 22, 2024 | finance.yahoo.com

Insulet Corporation (PODD)

May 19, 2024 | investorplace.com

Follow the Whales: 3 Genius Stocks the Smart Money Is Piling Into for Triple-Digit Gains

May 14, 2024 | au.investing.com

Blue Orca goes short Insulet on undisclosed preliminary injunction defeat

May 14, 2024 | finance.yahoo.com

Wall Street Trades Flat On Mixed Producer Inflation; Meme Stocks See Wild Ride, Bitcoin Drops: What's Driving Markets Tuesday?

May 14, 2024 | finance.yahoo.com

Will Insulet's Monopoly Crumble? Appellate Court Ruling Signals Shift in Automated Insulin Delivery Systems Market

May 14, 2024 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Insulet (PODD) and Crispr Therapeutics AG (CRSP)

May 14, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Mersana Therapeutics (MRSN), Insulet (PODD)

May 13, 2024 | benzinga.com

What the Options Market Tells Us About Insulet

May 13, 2024 | markets.businessinsider.com

Insulet (PODD) Gets a Hold from Stifel Nicolaus

May 13, 2024 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Insulet (PODD) and Progyny (PGNY)

May 12, 2024 | finance.yahoo.com

Results: Insulet Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts

May 12, 2024 | msn.com

Street calls of the week: Micron upgraded, downgrade for ZoomInfo

May 10, 2024 | markets.businessinsider.com

Insulet Corporation: Strong Q1 Performance and Positive Growth Outlook Affirm Buy Rating

May 10, 2024 | markets.businessinsider.com

Bank of America Securities Reaffirms Their Buy Rating on Insulet (PODD)

May 10, 2024 | finance.yahoo.com

Insulet Corp (PODD) Reports Strong Q1 2024 Results and Raises Full-Year Guidance

May 10, 2024 | finance.yahoo.com

Insulet Corporation (NASDAQ:PODD) Q1 2024 Earnings Call Transcript

May 9, 2024 | investorplace.com

PODD Stock Earnings: Insulet Beats EPS, Beats Revenue for Q1 2024

May 9, 2024 | seekingalpha.com

Insulet Corporation 2024 Q1 - Results - Earnings Call Presentation

May 9, 2024 | yahoo.com

Insulet misses first-quarter profit estimates as marketing costs weigh

May 9, 2024 | msn.com

Insulet Non-GAAP EPS of $0.23 misses by $0.16, revenue of $441.7M beats by $18.21M

May 9, 2024 | reuters.com

Insulet misses first-quarter profit estimates as marketing costs weigh

May 9, 2024 | businesswire.com

Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year

See More Headlines

Company Calendar

Last Earnings: 5/09/2024
Today: 5/31/2024
Next Earnings (Estimated): 8/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: Health Care Equipment
Current Symbol: NASDAQ:PODD
CUSIP: 45784P10
CIK: 1145197
Web: www.insulet.com
Phone: (978) 600-7000
Fax: 978-600-0120
Employees: 3,000
Year Founded: 2000

Price Target and Rating

Average Stock Price Target: $239.18
High Stock Price Target: $330.00
Low Stock Price Target: $184.00
Potential Upside/Downside: +35.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 18 Analysts

Profitability

EPS (Most Recent Fiscal Year): $3.30
Trailing P/E Ratio: 53.69
Forward P/E Ratio: 56.97
P/E Growth: 3.1
Net Income: $206.30 million
Net Margins: 13.14%
Pretax Margin: 13.75%
Return on Equity: 34.06%
Return on Assets: 9.08%

Debt

Debt-to-Equity Ratio: 1.72
Current Ratio: 3.74
Quick Ratio: 2.75

Sales & Book Value

Annual Sales: $1.78 billion
Price / Sales: 6.97
Cash Flow: $3.90 per share
Price / Cash Flow: 45.39
Book Value: $11.29 per share
Price / Book: 15.69

Miscellaneous

Outstanding Shares: 70,040,000
Free Float: 69,711,000
Market Cap: $12.41 billion
Optionable: Optionable
Beta: 1.00

Social Links

Key Executives

Dr. James R. Hollingshead Ph.D. (Age 61)
President, CEO & Director
Comp: $2.88M
Ms. Lauren Budden (Age 49)
Group VP, Chief Accounting Officer & Controller
Comp: $794.05k
Mr. Mark Field (Age 53)
Senior VP & CTO
Comp: $954.14k
Mr. John Wodick Kapples (Age 64)
Senior VP & General Counsel
Comp: $1.02M
Ms. Shacey Petrovic (Age 51)
Director & Advisor
Comp: $28.57k
Mr. Eric Benjamin (Age 41)
Executive VP, Chief Product & Customer Experience Officer
Comp: $1.14M
Ms. Ana Maria Chadwick (Age 52)
Executive VP, CFO & Treasurer
Mr. Prem Singh (Age 47)
Senior Vice President of Global Operations
Ms. Deborah R. Gordon CPA (Age 53)
Vice President of Investor Relations
Ms. Laetitia Cousin (Age 48)
Senior VP of Regulatory Affairs, Quality Assurance & Compliance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PODD Stock Analysis - Frequently Asked Questions

Should I buy or sell Insulet stock right now?: 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 3 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PODD shares.
View PODD analyst ratings or view top-rated stocks.
What is Insulet's stock price target for 2024?: 18 analysts have issued 1-year price targets for Insulet's shares. Their PODD share price targets range from $184.00 to $330.00. On average, they anticipate the company's share price to reach $239.18 in the next twelve months. This suggests a possible upside of 35.0% from the stock's current price.
View analysts price targets for PODD or view top-rated stocks among Wall Street analysts.
How have PODD shares performed in 2024?: Insulet's stock was trading at $216.98 at the beginning of 2024. Since then, PODD stock has decreased by 18.3% and is now trading at $177.19.
View the best growth stocks for 2024 here.
Are investors shorting Insulet?: Insulet saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,260,000 shares, an increase of 44.9% from the April 30th total of 2,940,000 shares. Based on an average daily trading volume, of 947,900 shares, the days-to-cover ratio is presently 4.5 days.
View Insulet's Short Interest.
When is Insulet's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our PODD earnings forecast.
How were Insulet's earnings last quarter?: Insulet Co. (NASDAQ:PODD) released its quarterly earnings data on Thursday, May, 9th. The medical instruments supplier reported $0.73 EPS for the quarter, beating the consensus estimate of $0.39 by $0.34. The medical instruments supplier earned $441.70 million during the quarter, compared to analysts' expectations of $424.05 million. Insulet had a net margin of 13.14% and a trailing twelve-month return on equity of 34.06%. The company's revenue for the quarter was up 23.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.23 earnings per share.

What ETFs hold Insulet's stock?: ETFs with the largest weight of Insulet (NASDAQ:PODD) stock in their portfolio include BTD Capital Fund (DIP), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT), Fidelity Disruptive Medicine ETF (FMED), Goldman Sachs Future Health Care Equity ETF (GDOC), Tema Cardiovascular and Metabolics ETF (HRTS) and Invesco Focused Discovery Growth ETF (IVDG).
What guidance has Insulet issued on next quarter's earnings?: Insulet updated its second quarter 2024 earnings guidance on Thursday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $456.0 million-$467.9 million, compared to the consensus revenue estimate of $457.8 million.
What is Shacey Petrovic's approval rating as Insulet's CEO?: 61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Insulet own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).
Who are Insulet's major shareholders?: Insulet's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.71%), Capital Research Global Investors (10.80%), Baillie Gifford & Co. (2.06%), Clearbridge Investments LLC (1.81%), William Blair Investment Management LLC (1.36%) and Westfield Capital Management Co. LP (0.67%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Dan Manea, James Hollingshead, Luciana Borio, Michael P Spears, Prem Singh, Sally Crawford, Shacey Petrovic, Timothy J Scannell and Wayde D Mcmillan.
View institutional ownership trends.
How do I buy shares of Insulet?: Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PODD) was last updated on 6/1/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Insulet (PODD) Stock Price, News & Analysis

Insulet MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows